Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: Rationale and promise

BioDrugs

Volumn 21, Issue 2, 2007, Pages 85-95

  Krymskaya, Vera P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TRL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; EVEROLIMUS; HAMARTIN; LEUKOTRIENE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; S6 KINASE; TEMSIROLIMUS; TUBERIN; WORTMANNIN;

ASTHMA; BREATHING MUSCLE; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG INHIBITION; ENERGY ABSORPTION; HUMAN; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ASTHMA; BRONCHI; CELL PROLIFERATION; HUMANS; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TRACHEA; TUMOR SUPPRESSOR PROTEINS;

EID: 34247182075     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721020-00003     Document Type: Review

References (159)

1. Boushey HA, Holtzman MJ, Sheller JR, et al. State of the art: bronchial hyperreactivity. Am Rev Resp Dis 1980; 121: 389-413
2. Woolcock AJ. Asthma: what are the important experiments? State of the art/conference summary. Am Rev Resp Dis 1989; 138: 730-44
3. Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thoracic Soc 2006; 3 (3): 276-80
4. Holgate ST. Exacerbations: the asthma paradox. Am J Resp Crit Care Med 2005; 172 (8): 941-3
5. Barnes N. Outcome measures in asthma. Thorax 2000; 55 Suppl.: 70S-74
6. Panettieri RA, Grunstein MM. Airway smooth muscle hyperplasia and hypertrophy. In: Barnes PJ, Grunstein MM, Leff AR, et al. editors. Asthma. Philadelphia (PA): Lippincott-Raven; 1997: 823-42
7. Homer RJ, Elias JA. Airway remodeling in asthma: therapeutic implications of mechanisms. Physiology 2005; 20 (1): 28-35
8. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Resp Crit Care Med 2001; 164 (10 Suppl.): 28S-38
9. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2004; 1 (3): 176-83
10. Aoshiba K, Nagai A. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease. Clin Rev Allergy Immunol 2004; 1: 35-43
11. Black JL. Asthma: more muscle cells or more muscular cells? Am J Respir Crit Care Med 2004; 169 (9): 980-1
12. Dunnill MS. The pathology of asthma, with special reference to the changes in the bronchial mucosa. J Clin Pathol 1960; 13: 27-33
13. Dunnill MS, Massarella GR, Anderson JA. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax 1969; 24: 176-9
14. Hossain S. Quantitative measurement of bronchial muscle in asthma. Am Rev Resp Dis 1973; 107: 99-109
15. Ebina M, Takahashi T, Chiba T, et al. Cellular hypertrophy and hyperplasia of airway smooth muscle underlying bronchial asthma: a 3-D morphometric study. Am Rev Resp Dis 1993; 148: 720-6
16. Lazaar AL, Panettieri RA. Airway smooth muscle as an immunomodulatory cell: a new target for pharmacotherapy? Curr Opin Pharmacol 2001; 1: 259-64
17. Woodruff PG, Dolganov GM, Ferrando RE, et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Resp Crit Care Med 2004; 169 (9): 1001-6
18. Woodruff PG. Airway remodeling in asthma. Semin Resp Crit Care Med 2002; 23: 361-8
19. Benayoun L, Druilhe A, Dombret M-C, et al. Airway structural alterations selectively associated with severe asthma. Am J Resp Crit Care Med 2003; 167 (10): 1360-8
20. Panettieri J, Reynold A. Airway smooth muscle: an immunomodulatory cell. J Allergy Clin Immunol 2002; 110 Suppl.: S269-74
21. Thomas CF, Limper AH. Phosphatidylinositol kinase regulation of airway smooth muscle cell proliferation. Am J Resp Cell Mol Biol 2000; 23 (4): 429-30
22. Page K, Hershenson MB. Mitogen-activated signaling and cell cycle regulation in airway smooth muscle. Front Biosci 2000; 5: d258-67
23. Condliffe AM, Cadwallader KA, Walker TR, et al. Phosphoinositide 3-kinase: a critical signaling event in pulmonary cells. Resp Res 2000; 1: 24-9
24. Halayko AJ, Kartha S, Stelmack GL, et al. Phophatidylinositol-3 kinase/mammalian target of rapamycin/p70s6k regulates contractile protein accumulation in airway myocyte differentiation. Am J Resp Cell Molec Biol 2004; 31 (3): 266-75
25. Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Ann Rev Biochem 2001; 70 (1): 535-602
26. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Ann Rev Biochem 2001; 70 (1): 247-79
27. Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005; 30 (4): 194-204
28. Chantry D, Vojtek A, Kashishian A, et al. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997; 272: 19236-41
29. Stoyanov B, Volonia S, Hanck T, et al. Cloning and characterization of a G protein-activated human phosphoinositide 3-kinase. Science 1995; 269: 690-3
30. Domin J, Gaidarov I, Smith MEK, et al. The class II phosphoinositide 3-kinase PI3K-α is concentrated in the trans-Golgi network and present in clatrin-coated vesicles. J Biol Chem 2000; 275: 11943-50
31. Volinia S, Dhand R, Vanhaesebroeck B, et al. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J 1995; 14: 3339-48
32. Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Ann Rev Immunol 2004; 22 (1): 563-98
33. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease. BioEssays 2002; 24: 65-71
34. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Ann Rev Cell Develop Biol 2001; 17 (1): 615-75
35. Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J Biol Chem 1999; 274: 10963-8
36. Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 1999; 283: 393-7
37. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19: 2537-48
38. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90
39. Krymskaya VP. Tumor suppressors hamartin and tuberin: intracellular signaling. Cell Signal 2003; 15: 729-39
40. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000; 97: 6085-90
41. Moses J. LAM and other diseases characterized by smooth muscle proliferation. New York: Marcel Dekker, Inc., 1999
42. Johnson SR, Tattersfield AE. Lymphangioleiomyomatosis. Semin Resp Crit Care Med 2002; 23: 85-92
43. Sullivan EJ. Lymphangioleiomyomatosis. Chest 1998; 114: 1689-703
44. Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Resp Cell Molec Biol 2003; 28 (5): 546-50
45. Inoki K, Corradetti MN, Guan K-L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37 (1): 19-24
46. Findlay GM, Harrington LS, Lamb RF. TSC1-2 tumor suppressor and regulation of mTOR signalling: linking cell growth and proliferation? Curr Opin Genet Develop 2005; 15 (1): 69-76
47. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005; 24 (50): 7475-81
48. Nobukini T, Thomas G. The mTOR/S6K signaling pathway: the role of the TSC1/2 tumor suppressor complex and the proto-oncogene Rheb. Novartis Foundation Symposium 2005; 262: 148-59
49. Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000; 2: 281-7
50. Goncharova E, Goncharov D, Noonan D, et al. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 2004; 167 (6): 1171-82
51. Onda H, Lueck A, Marks PW, et al. Tsc2+/- mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687-95
52. Kobayashi E, Minowa O, Kuno J, et al. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999; 59: 1206-11
53. Kobayashi T, Minowa O, Sugitani Y, et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 2001; 98 (15): 8762-7
54. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525-34
55. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 2002; 277: 30958-67
56. McManus EJ, Alessi DR. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol 2002; 4: E214-6
57. Manning BD, Tee AR, Longdon MN, et al. Identification of the tuberous sclerosis scomplex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt/PKB pathway. Mol Cell 2002; 10: 151-62
58. Castro AF, Rebhun JF, Clark GG, et al. Rheb binds TSC2 and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003; 278: 32493-6
59. Garami A, Zwartruis FJT, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: 1457-66
60. Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Devel 2003; 17 (15): 1829-34
61. Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13 (15): 1259-68
62. Tee AR, Anjum R, Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase (PI3K)/Akt/PKB-dependent and -independent phosphorylation of tuberin. J Biol Chem 2003; 278: 37288-96
63. Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol 2005; 15 (8): 702-13
64. Long X, Ortiz-Vega S, Lin Y, et al. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 2005; 280 (25): 23433-6
65. Pan D, Dong J, Zhang Y, et al. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol 2004; 14 (2): 78-85
66. Inoki K, Ouyang H, Li Y, et al. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005; 69 (1): 79-100
67. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-62
68. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17 (6): 596-603
69. Brunn GJ, Fadden P, Haystead TAJ, et al. The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-pro motif and is activated by antibodies to a region near its COOH terminus. J Biol Chem 1997; 272 (51): 32547-50
70. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10 (3): 457-68
71. Sarbassov DD, Siraj MA, Kim D-H. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14 (14): 1296-302
72. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6 (11): 1122-8
73. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB/PKB by the Rictor-mTOR complex. Science 2005; 307 (5712): 1098-101
74. Yang Q, Inoki K, Kim E, et al. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci U S A 2006; 103 (18): 6811-6
75. Sigal NH, Lin CS, Siekierka JJ. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. Transplant Proc 1991; 23: 1-5
76. Chung J, Kuo CJ, Crabtree GR, et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-36
77. Kuo CJ, Chung J, Fiorentino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358: 70-3
78. Price DJ, Grove JR, Calvo V, et al. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973-7
79. Burnett PE, Barrow RK, Cohen NA, et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998; 95: 1432-7
80. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by mammalian target of rapamycin. Science 1997; 277: 99-101
81. Avruch J. Insulin signal transduction through protein kinase cascades. Mol Cell Biochem 1998; 182: 31-48
82. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol 2004; 5: 827-35
83. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-71
84. Gout I, Minami T, Hara K, et al. Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase β containing proline-rich region. J Biol Chem 1998; 273: 30061-4
85. Nurse P. Cyclin dependent kinases and cell cycle control. Biosci Rep 2002; 22: 487-99
86. Nurse P. Genetic control of cell size at cell division in yeast. Nature 1975; 256: 547-51
87. Johnston GC, Pringle JR, Hartwell LH. Coordination of growth with cell division in the yeast Sacchromyces cerevisiae. Exp Cell Res 1977; 105: 79-98
88. Neufeld TP, de la Cruz AFA, Johnston LA, et al. Coordination of growth and cell division in the Drosophila wing. Cell 1998; 93 (7): 1183-93
89. Weigmann K, Cohen S, Lehner C. Cell cycle progression, growth and patterning in imaginal discs despite inhibition of cell division after inactivation of Drosophila Cdc2 kinase. Development 1997; 124 (18): 3555-63
90. Montagne J, Stewart MJ, Stocker H, et al. Drosophila S6 kinase: a regulator of cell size. Science 1999; 285: 2126-9
91. Pende M, Um SH, Mieulet V, et al. S6K1-/-/S6K2-/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent s6 kinase pathway. Mol Cell Biol 2004; 24 (8): 3112-24
92. Ohanna M, Sobering AK, Lapointe T, et al. Atrophy of S6K1-/- skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol 2005; 7 (3): 286-94
93. Billington CK, Kong KC, Bhattacharyya R, et al. Cooperative regulation of p70s6 kinase by receptor tyrosine kinases and G protein-coupled receptors augments airway smooth muscle growth. Biochemistry 2005; 44 (44): 14595-605
94. Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Resp Res 2003; 4 (2): 1-23
95. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-54
96. Leopoldt D, Hanck T, Exner T, et al. Gβγ stimulates phosphoinositide 3-kinase-γ by direct interaction with two domains of catalytic p110 subunit. J Biol Chem 1998; 273: 7024-9
97. Lopez-Ilasaca M, Crespo P, Pellici PG, et al. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ. Science 1997; 275: 394-7
98. Dekker LV, Segal AW. Signals to move cells. Science 2000; 287: 982-5
99. Krymskaya VP, Penn RB, Orsini MJ, et al. Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation. Am J Physiol 1999; 277: L65-78
100. Krymskaya VP, Hoffman R, Eszterhas A, et al. EGF activates ErbB2 and stimulates phosphatidylinositol 3-kinase in human airway smooth muscle cells. Am J Physiol 1999; 276: L246-55
101. Orsini MJ, Krymskaya VP, Eszterhas AJ, et al. MAPK superfamily activation in human airway smooth muscle cell: mitogenesis requires prolonged p42/p44 activation. Am J Physiol 1999; 277: L479-88
102. Ammit AJ, Kane SA, Panettieri RA. Activation of K-p21ras and N-p21ras, but not H-p21ras, is necessary for mitogen-induced human airway smooth-muscle proliferation. Am J Resp Cell Molec Biol 1999; 21: 719-27
103. Scott PH, Belham CM, Al-Hafidh J, et al. A regulatory role for cAMP in phosphatidylinositol 3-kinase/p70 ribosomal S6 kinase-mediated DNA synthesis in platelet-derived-growth-factor-stimulated bovine airway smooth-muscle cells. Biochem J 1996; 318: 965-71
104. Krymskaya VP, Orsini MJ, Eszterhas AJ, et al. Mechanisms of proliferation synergy by receptor tyrosine kinase and G protein-coupled receptor activation in human airway smooth muscle. Am J Resp Cell Molec Biol 2000; 23 (4): 546-54
105. 1 expression in airway smooth muscle cells. J Biol Chem 1999; 274: 22065-71
106. Page K, Li J, Wang Y, et al. Regulation of cyclin D1 expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells. Am J Resp Cell Molec Biol 2000; 23 (4): 436-43
107. Krymskaya VP, Goncharova EA, Ammit AJ, et al. Src is necessary and sufficient for human airway smooth muscle cell proliferation and migration. FASEB J 2005; 19: 428-30
108. Krymskaya VP, Ammit AJ, Hoffman RK, et al. Activation of class IA phosphatidylinositol 3-kinase stimulates DNA synthesis in human airway smooth muscle cells. Am J Physiol 2001; 280: L1009-18
109. Roche S, Koegl M, Courtneidge SA. The phosphatidylinositol 3-kinase α is required for DNA synthesis induced by some, but not all, growth factors. Proc Natl Acad Sci U S A 1994; 91: 9185-9
110. Valius M, Kazlauskas A. Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993; 73: 321-34
111. McIlroy J, Chen D, Wjasow C, et al. Specific activation of p85-p110 phosphatidylinositol 3′-kinase stimulates DNA synthesis by ras- and p70 S6 kinase-dependent pathways. Mol Cell Biol 1997; 17: 248-55
112. Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidyli-nositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998; 18: 5699-711
113. Weiss RH, Apostolids A. Dissociation of phosphatidylinositol 3-kinase activity and mitogenic inhibition in vascular smooth muscle cells. Cell Signal 1995; 7: 113-22
114. Saward L, Zahradka P. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997; 81: 249-57
115. Bacqueville D, Casagrande F, Perret B, et al. Phosphatidylinositol 3-kinase inhibitors block aortic smooth muscle cell proliferation in mid-late G1 phase: effect on cyclin-dependent kinase 2 and the inhibitory protein p27KIP1. Biochem Biophys Res Commun 1998; 244: 630-6
116. Hu ZW, Shi XY, Hoffman BB. ?1 Adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular muscle cells. J Biol Chem 1996; 271: 8977-82
117. Takahashi T, Kawahara Y, Okuda M, et al. Angiotensin II stimulates mitogen-activated protein kinases and protein synthesis by a Ras-independent pathway in vascular smooth muscle cells. J Biol Chem 1997; 272: 16018-22
118. Carpenter CL, Cantley LC. Phosphoinositide 3-kinase and the regulation of cell growth. Biochim Biophys Acta 1996; 1288: M11-6
119. Panettieri RA, Hall IP, Maki CS, et al. α-Thrombin increases cytosolic calcium and induces human airway smooth muscle cell proliferation. Am J Resp Cell Molec Biol 1995; 13: 205-16
120. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Ann Rev Cell Develop Biol 1997; 13: 513-609
121. Brown MT, Cooper JA. Regulation, substrates and functions of Src. Biochim Biophys Acta 1996; 1287: 121-49
122. Tsang F, Hwa Choo H, Dawe GS, et al. Inhibitors of the tyrosine kinase signaling cascade attenuated thrombin-induced guinea pig airway smooth muscle cell proliferation. Biochem Biophys Res Commun 2002; 293 (1): 72-8
123. Sayeski PP, Ali MS. The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Exp Cell Res 2003; 287 (2): 339-49
124. Luttrell LM, Ferguson SSG, Daaka Y, et al. β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes. Science 1999; 283: 655-61
125. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22 (7): 368-76
126. Yano H, Nakanashi S, Kimura K, et al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem 1993; 268: 25846-56
127. Bonser RW, Thompson NT, Randall RW, et al. Demethoxyviridin and wortmannin block phospholipase C and D activation in human neutrophil. Br J Pharmacol 1991; 103: 1237-41
128. Vemuri GS, Rittenhouse SE. Wortmannin inhibits serum-induced activation of phosphoinositide 3-kinase and proliferation of CHRF-288 cells. Biochem Biophys Res Commun 1994; 202: 1619-23
129. Kapeller R, Cantley LC. Phosphatidylinositol 3-kinase. BioEssays 1994; 16: 565-76
130. Hu Q, Klippel A, Muslin AJ, et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995; 268: 100-2
131. Klippel A, Reinhard C, Kavanaugh WM, et al. Membrane localization of phospha-tidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 1996; 16: 4117-27
132. S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994; 370: 71-5
133. S6K function is essential for G1 progression. Nature 1993; 363: 170-2
134. Monfar M, Lemon KP, Grammer TC, et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol Cell Biol 1995; 15: 326-37
135. s6k. EMBO J 1997; 16: 3693-704
136. s6k by PDK1. Science 1998; 279: 707-10
137. Alessi DR, Kozlowski MT, Weng Q, et al. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 1997; 8: 69-81
138. Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Resp Res 2006; 9: 73
139. Giembycz MA. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2005; 2 (4): 326-33
140. Spina D. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflam Allergy 2004; 3: 231-6
141. Vignola AM. PDE4 inhibitors in COPD: a more selective approach to treatment. Resp Med 2004; 98 (6): 495-503
142. Leung SY, Eynott P, Nath P, et al. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. J Allergy Clin Immunol 2005; 115 (5): 989-96
143. Henderson WR Jr, Chiang GKS, Tien Y-T, et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Resp Crit Care Med 2006; 173 (7): 718-28
144. Stewart AG. Airway wall remodelling and hyperresponsiveness: modelling remodelling in vitro and in vivo. Pulmon Pharmacol Ther 2001; 14 (3): 255-65
145. Strek ME. Difficult asthma. Proc Am Thoracic Soc 2006; 3 (1): 116-23
146. Toews ML, Ediger TL, Romberger DJ, et al. Lysophosphatidic acid in airway function and disease. Biochim Biophys Acta 2002; 1582 (1-3): 240-50
147. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT/PKB pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4 (12): 988-1004
148. Simon JA. Using isoform-specific inhibitors to target lipid kinases. Cell 2006; 125 (4): 647-9
149. Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5 (12): 921-9
150. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt/PKB pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
151. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006; 125 (4): 733-47
152. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006; 441 (7091): 366-70
153. Fan Q-W, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9 (5): 341-9
154. Camps M, Ruckle T, Ji H, et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. 2005; 11 (9): 936-43
155. Barber DF, Bartolome A, Hernandez C, et al. PI3Kγ inhibition blocks glomerulo-nephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11 (9): 933-5
156. Ohashi PS, Woodgett JR. Modulating autoimmunity: pick your PI3 kinase. Nat Med 2005; 11 (9): 924-5
157. Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol 2002; 12 (6): 735-41
158. Bjornsti M-A, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4 (5): 335-48
159. Zhou L, Goldsmith AM, Bentley JK, et al. 4E-Binding protein phosphorylation and eukaryotic initiation factor-4E release are required for airway smooth muscle hypertrophy. Am J Resp Cell Molec Biol 2005; 33 (2): 195-202